| Field | Specification |
|---|---|
| Target | |
| Alternative names | 11F8, IMC-11F8, LY3012211 |
| UniProt # | |
| CAS no. | |
| Reactivity | |
| Applications | |
| Assay type | |
| Sample type(s) | Plasma, Serum |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Assay Principle
This microplate immunoassay quantifies Necitumumab by colorimetric detection: samples and kit standards are processed in parallel, and absorbance values are converted to concentrations through the per-plate standard curve.
Background
Necitumumab (IMC-11F8, LY3012211) is a second-generation fully human immunoglobulin (Ig) G1 kappa isotype monoclonal antibody (mAb) that acts as an antagonist to direct against the extracellular region of epidermal growth factor receptor (EGFR). It was developed by Eli Lilly & Co (Indianapolis, IN, USA) and produced in genetically engineered mammalian NS0 cells. It was first approved by the U.S. Food and Drug Administration (FDA) under the brand name Portrazza in 2015, for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). After that, it has gained the approval for marketing in the Europe Union and Japan respectively in 2016 and 2017. It is not indicated for treatment of non-squamous NSCLC. Currently, there are several ongoing clinical trials investigating necitumumab in the treatment of NSCLC in several di铿€erent settings. It is currently being studied in combination with pre-existing agents, such as osimertinib, pembrolizumab, nabpaclitaxel, and carboplatin, as well as with new agents under investigation, abemaciclib and AZD9291. Necitumumab is currently being evaluated in the second-line setting following treatment failure or progression with front-line EGFR tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy.
Specifications
| Assay Type | Quantitative Colorimetric ELISA |
|---|---|
| Detection Method | Colorimetric |
| Plate Format | 96-well (96T) |
| Sample Types | Plasma, Serum |
| Sensitivity | 0.156 μg/mL |
| Detection Range | 0.31-5 μg/mL |
| Recovery | 80-120% |
| Stability & Storage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Shipping | 2-8 °C |
| CAS Number | 906805-06-9 |
| UniProt | P00533 |
| Alternative Names | 11F8, IMC-11F8, LY3012211 |
Performance Data
Performance is defined by a quantitative range of 0.31-5 μg/mL, an analytical sensitivity of 0.156 μg/mL, typical spike recovery of 80-120%. For best precision, target the central portion of the curve and confirm matrix behavior with spike-recovery and dilution-linearity checks before routine runs.
Target Notes
The target is also referenced in the literature as 11F8, IMC-11F8, LY3012211. Curated target information is available under UniProt accession P00533. The corresponding compound is registered under CAS 906805-06-9.
Common Research Applications
- Pharmacokinetic profiling of the drug in preclinical and translational research models
- Bioanalytical method development, bridging, and comparability studies
- Stability and formulation studies requiring reproducible concentration readouts
Safety & Handling
For Research Use Only. Not for diagnostic or therapeutic use. Handle all reagents and samples according to your institution's laboratory safety guidelines, and store components as recommended to preserve assay performance.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.